S 2474
Latest Information Update: 15 Jul 2002
Price :
$50 *
At a glance
- Originator Shionogi
- Class Analgesics; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories
- Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 15 Jul 2002 Discontinued - Phase-I for Rheumatoid arthritis in Japan (PO)
- 15 Jul 2002 Discontinued - Phase-II for Rheumatoid arthritis in Europe (PO)
- 29 May 2001 S 2474 is available for licensing (http://www.shionogi.co.jp)